Exendin-4 Alleviates Steatosis in an In Vitro Cell Model by Lowering FABP1 and FOXA1 Expression via the Wnt/-Catenin Signaling Pathway

The authors investigated the mechanisms underlying the protective effect of glucagon-like peptide-1 receptor (GLP-1R) on non-alcoholic fatty liver disease using an in vitro model of steatosis treated with the GLP-1R agonist Exendin-4.